Sign Up / Log In
Haematological Malignancies Watch Time: 39 Minutes

touchTALKS Exploring the changing landscape in Waldenström’s macroglobulinaemia: How will emerging BTK inhibitors alter patient outcomes?

Join Dr Alessandra Tedeschi as she highlights the latest data on second-generation Bruton’s tyrosine kinase inhibitors in the management of Waldenström’s macroglobulinaemia.

 
Video Chapters
Second-generation BTK inhibitors for patients with WM: What is the potential for improving outcomes?

Dr Alessandra Tedeschi highlights the effectiveness and limitations of first-generation Bruton’s tyrosine kinase (BTK) inhibitors in the management of people with Waldenström’s macroglobulinaemia, and outlines emerging efficacy data from clinical trials of second-generation BTK inhibitors.

view bio and disclosures
1/3 Next Chapter
 
Video Chapters
Maximizing outcomes for patients with WM: Adverse events associated with second-generation BTK inhibitors

Dr Alessandra Tedeschi overviews the adverse event profile of first-generation BTK inhibitors in treating Waldenström’s macroglobulinaemia, and walks us through the safety data from recent clinical trials of emerging second-generation BTK inhibitors.

view bio and disclosures
2/3 Next Chapter
 
Video Chapters
Using BTK inhibitors in clinical practice: How is the landscape changing?

Dr Alessandra Tedeschi reviews current international recommendations for the management of Waldenström’s macroglobulinaemia.

view bio and disclosures
3/3 Leave Feedback
Leave Feedback
Overview & Learning Objectives
Overview

In this activity, Dr Alessandra Tedeschi, an expert in Waldenström’s macroglobulinaemia (WM), discusses emerging second-generation Bruton’s tyrosine kinase (BTK) inhibitors in development for the treatment of people with WM, and provides an overview of current management practices.

Learning Objectives

After watching this activity, participants should be better able to:

  • Evaluate the new and emerging efficacy data for second-generation BTK inhibitors in patients with WM
  • Summarize the adverse events associated with second-generation BTK inhibitors
  • Review current management recommendations for people with Waldenström’s macroglobulinaemia
Faculty & Disclosures
Dr Alessandra Tedeschi

Niguarda Cancer Centre, Milan, Italy

Dr Alessandra Tedeschi is a Consultant Haematologist in the Oncology/Haematology Department of the Niguarda Cancer Center, Milan, Italy.

Dr Tedeschi gained her medical degree from the University of Bologna, Bologna, Italy and completed her specialism in haematology specialty at the University of Ancona, Italy. From 1996 to 1999, she carried out research in the Haematology Department of the Niguarda Cancer Center and completed an internship in the Leukemia Department of the MD Anderson Cancer Center, Houston, Texas, USA.

Dr Tedeschi has a specific interest in the treatment of chronic lymphoproliferative disorders, in particular chronic lymphocytic leukaemia and Waldenström’s macroglobulinaemia. She is principal investigator for numerous clinical trials.

Disclosures:

Consulting services for AbbVie, AstraZeneca, BeiGene and Janssen-Cillag SpA

This content is intended for healthcare professionals only. Please confirm that you are a healthcare professional.

Accept Decline
Feedback Close
Feedback

Please provide feedback for this touchTALKS on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar